April 27, 2023 News by Marisa Wexler, MS AAN 2023: Aubagio reduced risk of developing MS symptoms in RIS trial Treatment with Aubagio (teriflunomide) significantly reduces the risk that adults with radiologically isolated syndrome (RIS) will develop symptoms of multiple sclerosis (MS), new clinical trial data show. This is the second trial showing that approved disease-modifying therapies can delay the development of MS in people who have…
February 4, 2022 News by Margarida Maia, PhD Researcher Will Use Award to Find Biomarkers of RIS in Children This yearās Harry Weaver Neuroscience Scholar Award, funded by the National Multiple Sclerosis (MS) Society, has gone to a Yale University researcher who is searching for biomarkers of radiologically isolated syndrome (RIS) in children. RIS occurs when imaging findings on MRI scans are similar to those seen in people…
November 8, 2021 News by Marisa Wexler, MS Younger Age, Certain Lesions Linked to Higher MS Risk for RIS Patients Among people with nervous system damage indicative of multiple sclerosis (MS), but who don’t yet have the disease ā a condition known as radiologically isolated syndrome or RIS ā the risk of progressing to full-fledged MS is higher for those who are younger, have spinal cord lesions, and have…
May 10, 2021 Columns by Ed Tobias MS News That Caught My Eye Last Week: Early MS, Fenebrutinib, Restless Legs, Safer MRIs Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients Yes, you’re reading this right. This trial aims to see if Ocrevus can stop MS before it’s officially diagnosed ā when it may be smoldering and presenting a minimum of MS-like activity. In July, this…
May 7, 2021 News by Vanda Pinto, PhD Phase 4 Trial Will Test if Ocrevus Can Prevent MS Onset in RIS Patients Yale University is launching CELLO, a multicenter study to investigate the efficacy of Ocrevus (ocrelizumab) in treating people with lesions suggestive ofĀ multiple sclerosis (MS), a condition known as radiologically isolated syndrome. The Phase 4 study (NCT04877457) aims to evaluate whether short-term treatment with Ocrevus can…
July 14, 2020 News by Marisa Wexler, MS Most RIS Patients Likely to Progress to MS Within 10 Years, Study Says More than half of people with brain imaging changes akin to multiple sclerosis (MS) go on to develop the disease within 10 years, a global study of those with radiologically isolated syndrome reported. Progression to MS appears to be more likely in those who are younger, have spinal…
March 4, 2019 News by Jonathan Grinstein #ACTRIMS2019 – Two MRI Biomarkers Can Potentially Distinguish RIS from Other Disorders Two new magnetic resonance imaging (MRI) biomarkers ā called central vein sign and paramagnetic rim sign ā could be useful for differentiating true radiologically isolated syndrome (RIS) patients from those with mimicking features, new research shows. The findings were presented at theĀ Americas Committee for Treatment and Research in Multiple…
October 26, 2017 News by Patricia Silva, PhD #MSParis2017 – Researchers Disagree on Feasibility of Using Disease-modifying Therapies in RIS Patients Radiologically isolated syndrome (RIS) is a rare and relatively recent condition in which people have multiple sclerosis (MS)-like brain and spinal cord lesions without showing disease activity. But since the establishment of the RIS diagnosis, researchers have not reached an agreement on whether these patients should receive MS disease-modifying therapies.